Merck to acquire cancer drug maker Peloton Therapeutics for $1.05Bn

Merck to acquire cancer drug maker Peloton Therapeutics for $1.05Bn

Published: Just now By Mateen Dalal

The acquisition would help Merck strengthen its presence in the renal cell carcinoma space and support its cancer drug portfolio. U.S. pharmaceutical conglomerate, Merck & Co. Inc. has recently agreed to purchase Da....

Ikea invests in India’s one-stop interior design platform Livspace

The interior design platform had raised over $70 million last year with investment from TPG Growth & Goldman Sachs. The investment is Ikea’s first such deal in India, however it isn’t the company’s dalliance in Indi....

BioXcel unveils data from Phase 1 study of receptor agonist BXCL501

Sublingual administration of BXCL501 had achieved drug exposures that will be therapeutic for the acute treatment of agitation Reports confirm that BioXcel Therapeutics (BTI) has recently presented data from its Phase 1 pharmacokinetic (bi....

Kazia to team up with U.S. oncology group for brain cancer drug trial

A multi-centre phase-two study will represent the fourth clinical trial ongoing for Kazia’s GDC-0084 drug candidate Kazia Therapeutics Ltd, an Australian oncology-focused biotechnology company, has recently entered into a partnership....

GSK, Zymeworks expand partnership for bispecific antibody development

GSK anticipates using Zymeworks’ Azymetric technology for developing bispecifics drugs that treat communicable diseases Zymeworks Inc, a clinical-stage biopharmaceutical company, has recently announced that GSK has extended its 2016 ....

Vertex, Kymera join forces for developing protein degradation drugs

Vertex would be paying $70 million in advance to work with Kymera including an equity investment in the company Kymera Therapeutics and Vertex Pharmaceuticals Incorporated (VRTX) have reportedly announced that they are entering into a four....

Roche delays acquiring Spark as regulatory review process continues

Roche, the leading Swiss pharma has pushed back its scheduled acquisition of the gene therapy specialist, Spark Therapeutics for third time in a row, as it waits for the U.S. government to complete regulatory review of the proposed $4.3 bil....